IBYME   02675
INSTITUTO DE BIOLOGIA Y MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
. Endogenous galectin-1 plays a key role in inflammatory bowel disease
Autor/es:
MOROSI, LG; MORALES, RM; TOSCANO, M; RABINOVICH, GA ; MARIÑO, KV
Lugar:
Buenos Aires
Reunión:
Simposio; Primer Simposio Argentino de Glicobiología Glycoar2014; 2013
Institución organizadora:
FIL, IBYME, IFYBINE
Resumen:
Our laboratory investigates the anti-inflammatory and immunoregulatory roles of Galectin-1 (Gal-1), a glycan-binding protein that recognizes N- and O-glycans bearing the disaccharide N-acetyllactosamine (Galβ(1-4)-GlcNAc; LacNAc). With the overarching goal of studying the role of endogenous galectin-1 in mucosal homeostasis and intestinal immunoregulation and validating its therapeutic activity in inflammatory bowel disease, we optimized a model of 2,4,6-Trinitrobenzenesulfonic acid (TNBS)-induced colitis and evaluated the clinical outcome of wild-type and Gal-1 knock-out (Lgals1-/-) mice in the C57BL/6 background. Validation of the anti-inflammatory activity of Gal-1 in this model may allow the examination of cell surface glycosylation in cellular compartments of the mucosal microenvironment and the identification of Gal-1 function and may reveal a potential target for the treatment of human IBD, including Crohn?s disease and ulcerative colitis. Assessment of the clinical score of TNBS-injected mice revealed increased clinical severity in Lgals1-/-compared to WT mice, as shown by total weight loss and weight/length relationship of the colon (p<0.05). These results unveil the critical role of endogenous galectin-1 in regulating mucosal homeostasis during the development of inflammatory bowel disease.